Advertisement

Advanced Cell Technology Inc. (ACT) today released data from a U.S. clinical trial testing the safety of treating Stargardt’s macular dystrophy (SMD) with human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells. The news comes one day after the Marlborough company announced that it had started using its hESC on an SMD patient in a Phase 1/2 trial in Europe.

SOURCE

Advertisement
Advertisement